Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Surgery Partners, Inc.

Ticker
SGRY
Sector
Industry
Report date
November 9, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include Surgery Partners amending its merger agreement with HealthSpan Partners to increase the per-share consideration to $25.00 and reporting third quarter 2026 financial results showing slight revenue decline but improved same-facility performance. The company also secured improved merger terms following a rival bid and reported a net loss of $21.1 million for Q3 2026.

Recent developments:
  • Surgery Partners amended the HealthSpan Partners merger agreement to $25.00 per share and reported third quarter 2026 results [N1].
  • The company reported Q3 2026 earnings with a net loss of $21.1 million and adjusted EBITDA of $132.7 million, reflecting a slight revenue decrease but growth in same-facility revenues [N1][N2].
  • Surgery Partners amended its merger agreement with Spyglass Topco, increasing consideration to $25.00 per share [N3].
  • The company secured improved merger terms with HealthSpan following a rival bid, resulting in a positive stock reaction [N4].
  • Surgery Partners continues to focus on operational performance and strategic growth initiatives amid the merger process [N1][N2].
Overview

Surgery Partners, Inc. is a leading healthcare services company operating a national network of outpatient surgical facilities and ancillary services in the United States. Its portfolio includes ambulatory surgery centers and short-stay surgical hospitals primarily focused on non-emergency, elective surgical procedures across various specialties such as orthopedics, ophthalmology, gastroenterology, and general surgery. The company owns or operates facilities through partnerships with physicians and health care systems, often holding majority ownership and providing day-to-day management services. Revenue is generated mainly from facility fees for surgical services, with a payor mix dominated by private insurance and government programs. Surgery Partners pursues growth through organic expansion, physician engagement, acquisitions, new service offerings, and strategic partnerships with payors and health systems. The company faces competition from hospitals and other surgical facility operators and emphasizes quality of care, convenience, and physician relationships as competitive advantages. As of September 30, 2026, Surgery Partners operated 173 surgical facilities across 30 states and reported $815.3 million in revenues for Q3 2026, with a net loss of $21.1 million and adjusted EBITDA of $132.7 million. The company is currently undergoing a merger process with Spyglass Topco, LLC, which includes amended terms and is subject to customary closing conditions.

Executive summary

Surgery Partners, Inc. operates a large network of outpatient surgical facilities across the U.S., including ambulatory surgery centers and surgical hospitals, focusing on non-emergency, scheduled procedures across multiple specialties. The company pursues growth through organic expansion, acquisitions, physician partnerships, and strategic relationships with payors and health systems. As of September 30, 2026, it operated 173 facilities with majority ownership in 83. Recent financial results show a slight revenue decline year-over-year due to divestitures but growth in same-facility revenues. The company reported a net loss of $21.1 million and adjusted EBITDA of $132.7 million for Q3 2026. Surgery Partners has a strong liquidity position with $354.5 million in cash and a current ratio of 2.17. The company is in the process of a merger with Spyglass Topco, LLC, with amended terms increasing the per-share consideration to $25.00. The merger is subject to customary closing conditions and carries risks including potential failure to complete, business disruptions, and employee retention challenges. Financial figures are summarized from the latest SEC filings and are provided for informational purposes only — not financial advice [S2].

Scenarios for SGRY

Bull case model:

Surgery Partners benefits from favorable industry trends such as an aging population, advancements in medical technology, and shifts in surgical procedures from inpatient to outpatient settings, which expand the addressable market for ambulatory surgical centers. The company's multifaceted growth strategy, including organic growth, acquisitions, physician engagement, and strategic partnerships, supports revenue and earnings expansion. Its strong liquidity position and operational scale provide flexibility to pursue growth opportunities and enhance operational efficiencies. The ongoing merger with Spyglass Topco, LLC, with improved terms, may provide strategic benefits and shareholder value realization upon completion.

Bear case model:

Risks include potential failure to complete the pending merger, which could adversely affect the company's stock price, business relationships, and management focus. The merger process introduces uncertainties that may disrupt operations and employee retention. The company faces competitive pressures from hospitals, other surgical facility operators, and office-based procedures. Regulatory changes, reimbursement pressures from government and private payors, and potential litigation risks could negatively impact financial performance. Integration challenges from acquisitions and developments, supply chain issues, and the ability to attract and retain qualified healthcare professionals also pose risks to execution and growth.

Moat:

Surgery Partners' moat is supported by its extensive national network of surgical facilities, strategic partnerships with physicians and health care systems, and its integrated outpatient delivery model focused on cost-effective, high-quality surgical care. The company's scale and reputation facilitate access to favorable private insurance contracts and physician recruitment, which are critical competitive factors in the surgical services market. Its diversified specialty mix and ability to provide comprehensive financial, marketing, and operational support to its facilities enhance its competitive positioning. Additionally, the company's disciplined acquisition and development strategy and strategic relationships with payors and health systems contribute to its market presence and operational efficiencies. However, the company faces competition from large national healthcare providers and local hospitals, as well as trends toward office-based procedures, which may challenge its competitive advantages.

Risks overview
Risks summary
The most significant risk is the uncertainty surrounding the completion of the pending merger, which could materially affect the company's operations, financial condition, and stockholder value.
Risks details:

• Merger Completion Risk: The merger with Spyglass Topco, LLC is subject to customary closing conditions and may not be completed on the anticipated timeline or at all, which could materially adversely impact the business, financial condition, and stock price [S2].
• Operational Disruption and Employee Retention: The merger process may divert management attention, disrupt business relationships, and cause uncertainty among employees, potentially leading to loss of key personnel and reduced productivity [S2].
• Regulatory and Reimbursement Risks: Changes in Medicare, Medicaid, and private insurance reimbursement policies, as well as regulatory reforms, could adversely affect revenue and profitability [S1][S2].
• Competitive Pressures: Competition from hospitals, other surgical facility operators, and office-based surgical procedures may limit growth and market share [S1].
• Litigation and Legal Risks: The company may face securities class action and derivative lawsuits related to the merger or other matters, which could result in significant costs and distract management [S2].
• Integration and Growth Execution: Challenges in integrating acquisitions, developing new facilities, and attracting physicians and payors could impede growth and operational efficiency [S1][S2].

FINAL FORECAST FOR SGRY

Final take one line
Surgery Partners operates a large outpatient surgical network with detailed disclosures and recent merger activity providing very high business model visibility.
Final take 12 to 24 month view

Business trends: Growth driven by outpatient surgical services expansion, physician partnerships, and strategic acquisitions amid industry shifts toward ambulatory care.
Execution milestones: Completion of the merger with Spyglass Topco, integration of acquired facilities, and continued same-facility revenue growth.
Key risks: Merger completion uncertainty, operational disruptions during transition, regulatory reimbursement pressures, and competitive market dynamics.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Surgery Partners, Inc. is a Delaware corporation operating a national network of surgical facilities and ancillary services in the U.S. through subsidiaries [S1].
  • The company operates an integrated outpatient delivery model focused on high-quality, cost-effective surgical and ancillary care supporting patients and physicians [S1].
  • As of December 31, 2025, Surgery Partners owned or operated 176 surgical facilities across 30 states, including 157 ambulatory surgery centers (ASCs) and 19 licensed surgical hospitals [S1].
  • The surgical facilities provide primarily non-emergency, scheduled surgical procedures across multiple specialties such as orthopedics, pain management, ophthalmology, gastroenterology, and general surgery [S1].
  • The company owns a majority interest in 90 surgical facilities and consolidates 121 for financial reporting purposes [S1].
  • Revenue is primarily generated from facility fees for surgical services, excluding professional fees billed separately by physicians [S1].
  • The company’s payor mix in 2025 was approximately 52.3% private insurance, 42.8% government programs, 2.7% self-pay, and 2.2% other [S1].
  • Surgery Partners competes with hospitals and other surgical facility operators, emphasizing quality of care, convenience, physician relationships, and managed care participation [S1].
  • The company employs a growth strategy including organic growth, physician engagement, acquisitions, new service offerings, operational efficiencies, and strategic partnerships with payors and health systems [S1].
  • As of September 30, 2026, Surgery Partners owned or operated 173 surgical facilities (156 ASCs and 17 surgical hospitals) across 30 states, with majority ownership in 83 and consolidation of 115 facilities [S2].
  • Third quarter 2026 total revenues were $815.3 million, a 0.8% decrease from the prior year quarter, impacted by divestitures partially offset by same-facility revenue growth [S2].
  • Days adjusted same-facility revenues increased 6.0% in Q3 2026 compared to Q3 2025, driven by a 5.8% increase in revenue per case and a 0.2% increase in same-facility cases [S2].
  • Net loss attributable to Surgery Partners was $21.1 million in Q3 2026 compared to $22.7 million in Q3 2025 [S2].
  • Adjusted EBITDA for Q3 2026 decreased 2.7% to $132.7 million from $136.4 million in the prior year quarter [S2].
  • As of September 30, 2026, the company had $354.5 million in cash and cash equivalents and $692.8 million borrowing capacity under its revolving credit facility [S2].
  • On October 23, 2026, Surgery Partners entered into a merger agreement with Spyglass Topco, LLC, amended November 8, 2026, under which Surgery Partners will become a wholly owned subsidiary of the parent company, resulting in delisting and deregistration of its common stock [S2][N1][N3].
  • The merger consideration was amended to $25.00 per share [N1][N3].
  • The merger is subject to customary closing conditions including stockholder approval, regulatory approvals, and absence of material adverse effects [S2].
  • The company disclosed risks related to the merger including potential failure to complete the merger, adverse effects on stock price, business disruptions, employee retention challenges, litigation risks, and restrictions on business activities during the merger pendency [S2].
  • Surgery Partners amended the merger agreement with HealthSpan Partners, improving terms following a rival bid [N4].
  • Recent news highlights include the company beating Q3 earnings expectations and reporting third quarter 2026 results [N2][N1].
  • The company’s business model and operations are well documented in SEC filings and recent news, providing high clarity and consistency.
  • Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
  • Liquidity ratios as of September 30, 2026, include a current ratio of 2.17 and a cash ratio of 0.71, indicating a solid liquidity position [S2].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-02 | 10-K
  • S2 | 2026-11-09 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | Surgery Partners, Inc. Amends HealthSpan Partners Merger Agreement to $25.00 Per Share and Reports Third Quarter 2026 Results | https://www.nasdaq.com/articles/surgery-partners-inc-amends-healthspan-partners-merger-agreement-2500-share-and-reports
  • N2 | 2026-11-09 | www.nasdaq.com | Surgery Partners (SGRY) Beats Q3 Earnings Estimates | https://www.nasdaq.com/articles/surgery-partners-sgry-beats-q3-earnings-estimates
  • N3 | 2026-11-09 | www.nasdaq.com | Surgery Partners, Inc. Amends Merger Agreement with Spyglass Topco, Increasing Consideration to $25.00 Per Share | https://www.nasdaq.com/articles/surgery-partners-inc-amends-merger-agreement-spyglass-topco-increasing-consideration-2500
  • N4 | 2026-11-09 | www.nasdaq.com | Surgery Partners Secures Improved Merger Terms With HealthSpan Following Rival Bid; Stock Up | https://www.nasdaq.com/articles/surgery-partners-secures-improved-merger-terms-healthspan-following-rival-bid-stock
  • N5 | 2026-11-05 | www.nasdaq.com | Biodesix, Inc. (BDSX) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/biodesix-inc-bdsx-reports-q3-loss-lags-revenue-estimates
  • N6 | 2026-11-04 | www.nasdaq.com | CVS Health (CVS) Beats Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/cvs-health-cvs-beats-q3-earnings-and-revenue-estimates
  • N7 | 2026-10-30 | www.nasdaq.com | Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals | https://www.nasdaq.com/articles/weekly-buzz-abbv-pfe-win-fda-nod-artv-slashes-jobs-davi-sgry-strike-deals
  • N8 | 2026-10-26 | www.nasdaq.com | Stock Market Today, Oct. 26: Surgery Partners Skyrockets 48% on $5.7 Billion HealthSpan Acquisition | https://www.nasdaq.com/articles/stock-market-today-oct-26-surgery-partners-skyrockets-48-57-billion-healthspan-acquisition
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine